Jiuzhou Pharmaceutical - Public Comps and Valuation Multiples

Jiuzhou Pharmaceutical Overview

About Jiuzhou Pharmaceutical

Zhejiang Jiuzhou Pharmaceutical Co Ltd is a China-based pharmaceutical manufacturer. The company is primarily engaged in the manufacturing, research, development, and sale of active pharmaceutical ingredients, intermediates, asymmetric catalyst, and lithium battery materials. Its active pharmaceutical ingredient offerings include Carbamazepine, Duloxetine, Bezafibrate, Meropenem, Sulphadimethoxine Sodium, Oxcarbazepine, and Amprolium, among others. The firm also provides services of new drug contract development and manufacturing organization to the international pharmaceutical giant.

Founded

1973

HQ

Employees

4.9K+

Website

jiuzhoupharma.com

Sectors

Contract Research & Manufacturing
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $810M

LTM EBITDA $224M

EV

$2.1B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Jiuzhou Pharmaceutical Financials

As of December 2025, Jiuzhou Pharmaceutical reported last 12-month revenue of $810M and EBITDA of $224M.

In the same period, Jiuzhou Pharmaceutical generated $289M in LTM gross profit and $134M in net income.

See Jiuzhou Pharmaceutical valuation multiples based on analyst estimates

Jiuzhou Pharmaceutical P&L

In the most recent fiscal year, Jiuzhou Pharmaceutical reported revenue of $737M and EBITDA of $166M.

Jiuzhou Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Jiuzhou Pharmaceutical valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$810M	XXX	$737M	XXX	XXX	XXX
Gross Profit	$289M	XXX	$249M	XXX	XXX	XXX
Gross Margin	36%	XXX	34%	XXX	XXX	XXX
EBITDA	$224M	XXX	$166M	XXX	XXX	XXX
EBITDA Margin	28%	XXX	22%	XXX	XXX	XXX
EBIT	$160M	XXX	$129M	XXX	XXX	XXX
EBIT Margin	20%	XXX	17%	XXX	XXX	XXX
Net Profit	$134M	XXX	$86.6M	XXX	XXX	XXX
Net Margin	17%	XXX	12%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Jiuzhou Pharmaceutical including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $810M. EBITDA for the last twelve months was $224M. In the most recent fiscal year, Jiuzhou Pharmaceutical achieved $737M in revenue and $166M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$810M	Analyst estimates available to subscribers	$737M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$289M	Analyst estimates available to subscribers	$249M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	35.7% gross margin	Analyst estimates available to subscribers	33.8% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$224M	Analyst estimates available to subscribers	$166M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	27.7% EBITDA margin	Analyst estimates available to subscribers	22.5% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$160M	Analyst estimates available to subscribers	$129M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	19.7% EBIT margin	Analyst estimates available to subscribers	17.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$134M	Analyst estimates available to subscribers	$86.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	16.6% net profit margin	Analyst estimates available to subscribers	11.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Jiuzhou Pharmaceutical

This financial data table provides comprehensive performance metrics for Jiuzhou Pharmaceutical, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Jiuzhou Pharmaceutical generated $810M in revenue over the last twelve months.
The company achieved $224M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $289M.
Net income over the last twelve months reached $134M.

Fiscal Year Performance

In the most recent fiscal year, Jiuzhou Pharmaceutical reported $737M in total revenue.
Fiscal year EBITDA was $166M.
The company maintained a gross profit margin of 33.8% in the most recent fiscal year.
EBITDA margin for the fiscal year was 22.5%.
Net profit margin reached 11.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Jiuzhou Pharmaceutical. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Jiuzhou Pharmaceutical Stock Performance

Jiuzhou Pharmaceutical has current market cap of CNY 17.5B (or $2.5B), and EV of CNY 14.9B (or $2.1B).

Market Cap Evolution

Jiuzhou Pharmaceutical Stock Data

As of January 16, 2026, Jiuzhou Pharmaceutical's stock price is CNY 20 (or $3).

See Jiuzhou Pharmaceutical trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.1B	$2.5B	XXX	XXX	XXX	XXX	$0.15

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Jiuzhou Pharmaceutical Valuation Multiples

Jiuzhou Pharmaceutical's trades at 2.6x EV/Revenue multiple, and 9.5x EV/EBITDA.

See valuation multiples for Jiuzhou Pharmaceutical and 15K+ public comps

Jiuzhou Pharmaceutical Financial Valuation Multiples

As of January 16, 2026, Jiuzhou Pharmaceutical has market cap of $2.5B and EV of $2.1B.

Equity research analysts estimate Jiuzhou Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Jiuzhou Pharmaceutical has a P/E ratio of 18.6x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$2.5B	XXX	$2.5B	XXX	XXX	XXX
EV (current)	$2.1B	XXX	$2.1B	XXX	XXX	XXX
EV/Revenue	2.6x	XXX	2.6x	XXX	XXX	XXX
EV/EBITDA	9.5x	XXX	9.5x	XXX	XXX	XXX
EV/EBIT	13.3x	XXX	13.3x	XXX	XXX	XXX
EV/Gross Profit	7.4x	XXX	n/a	XXX	XXX	XXX
P/E	18.6x	XXX	18.6x	XXX	XXX	XXX
EV/FCF	n/a	XXX	145.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Jiuzhou Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Jiuzhou Pharmaceutical Margins & Growth Rates

Jiuzhou Pharmaceutical's last 12 month revenue growth is 8%

Jiuzhou Pharmaceutical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $25K for the same period.

Jiuzhou Pharmaceutical's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Jiuzhou Pharmaceutical's rule of X is 47% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Jiuzhou Pharmaceutical and other 15K+ public comps

Jiuzhou Pharmaceutical Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	8%	XXX	7%	XXX	XXX	XXX
EBITDA Margin	28%	XXX	28%	XXX	XXX	XXX
EBITDA Growth	8%	XXX	0%	XXX	XXX	XXX
Rule of 40	36%	XXX	35%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	47%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$25K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	1%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	6%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	16%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial